ELN Diagnostics MRD Contact  · 

Contact Persons in Project 12: MRD

Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2008/08/27

Name	Initials	E-mail	Clinic	Country
Lead Participants
D. Grimwade	GRI		King´s College	UK
Participants
G. Barbany *	BARB		Uppsala Universitet	Sweden
P. Bernasconi	BERA		Universita degli Studi di Pavia	Italy
B. Cassinat	CAS			France
D. Coriu	COR			Romania
N.C.P. Cross	CRO		University of Southampton	UK
S. Daly *	DAL		Central Manchester and Mancherster Children's University Hospitals NHS Trust	UK
J. Gabert	GABE			France
C. Gerbon *	GERB		IPSOGEN	France
L. Griskevicius	GRIS
F. Hermitte *	HER		IPSOGEN	France
A. Hochhaus	HOC		Ruprecht-Karls-Universität	Germany
P. Hokland	HOK		Aarhus University Hospital	Denmark
J.H. Jansen	JAN			Netherlands
J. Kaeda	KAE		Imperial College London	UK
T. Khalid	KHA			UK
M. Kneba	KNE		University Hospital Schleswig-Holstein, Campus Kiel	Germany
A. Kustanovich	KUST
F. Lo Cocco	LOC		Universitá degli Studi di Roma Tor Vergata	Italy
P. Martiat	MART		Jules Bordet Institute-Free University of Brussels	Belgium
G. Martinelli	MARG		Universitá di Bologna- Unita Complessa di Istituti di Cardiologia ed Ematologia	Italy
M. Müller	MUE			Germany
G.J. Mufti	MUFT		King´s College	UK
J. Nomdedeu	SIE		Institut de Recerca de l'Hospital de la Santa Creu i Sant Paul	Spain
E. Oppliger Leibundgut *	OPP			Switzerland
G.J. Ossenkoppele	OSS		VU Academic Medical Center	Netherlands
M. Ostergaard *	OST			Denmark
U. Ozbek	OZB			Turkey
R. Padua *	PAD		King´s College	UK
N. Pallisgaard	PAL		Odense University Hospital	Denmark
F. Pane	PAN		CEINGE Biotecnologie avanzate s.c.a.r.l.	Italy
C. Preudhomme	PRE		Centre Hospitalier-Régional, Universitaire de Lille	France
A. Reiter	REIT		Ruprecht-Karls-Universität	Germany
T. Sacha	SAC		Jagiellonian University, Medical College	Poland
G. Saglio	SAG		Università degli Studi di Torino	Italy
V. Savchenko *	SAV			Russia
N. Savva *	SAV
S. Schnittger *	SCHN		Münchner Leukämie Labor (MLL)	Germany
G.J. Schuurhuis	SCHU			Netherlands
C. Thiede	THIE		Technische Universität Dresden	Germany
K. Tobal	TOB		Central Manchester and Manchester Children´s University Hospitals NHS Trust	UK
G. Tsaur	TSA			Russia
V. van der Velden	VEL		Erasmus University Medical Center	Netherlands
J.J.M. van Dongen	DON		Erasmus University Medical Center	Netherlands
J. Yin	YIN		Central Manchester and Manchester Children´s University Hospitals NHS Trust	UK
A. Zaritskey	ZAR			Russia
* = Female Researcher

Lead Participants:

Dr. D. Grimwade (London, UK): Longstanding experience in identification of molecular and prognostic markers in AML, with a particular interest in acute promyelocytic leukemia (APL). Member of the UK Medical Research Council (MRC) Adult Leukemia Working Party and AML Working Group. Responsible for undertaking MRD monitoring studies in MRC ATRA trial for patients with APL. Responsible for co-ordinating molecular screening and MRD monitoring in MRC AML15 trial, in which RQ-PCR for the PML-RARA fusion for patients with APL is being used to determine treatment approach and monitor response to arsenic trioxide. Network Leader (AML1-ETO) for EAC consortium for detection of fusion gene targets in AML.

Participants:

Dr. G. Barbany (Stockholm, Sweden): This group has extensive experience of European networking and molecular diagnostics and MRD detection in the European context. They have focused particularly on MRD detection in CML and are currently evaluating responses to imatinib. Dr. Barbany served as an excellent network leader for the BCR-ABL (p210) group in the "Europe Against Cancer" program. Her group is currently establishing protocols for improved and standardized sample processing to maximise PCR sensitivity.

Dr. P. Bernasconi (Pavia, Italy): Experience in cytogenetics and molecular genetics in acute and chronic leukemias.

B. Cassinat (, France):

D. Coriu (, Romania):

Prof.Dr. N.C.P. Cross (Southampton, UK):

S. Daly (Manchester, UK):

J. Gabert (, France):

C. Gerbon (, France):

L. Griskevicius (, ):

F. Hermitte (13288 Marseille, France):

Prof.Dr. A. Hochhaus (Heidelberg, Germany):

Prof.Dr. P. Hokland (Aarhus, Denmark):

J.H. Jansen (, Netherlands):

Dr. J. Kaeda (London, UK): Experience in monitoring of residual disease in CML.

T. Khalid (, UK):

Prof.Dr. M. Kneba (Kiel, Germany): Coordinator of the expert group of MRD of the German Competence Network „Acute and chronic leukemias“.

A. Kustanovich (, ):

Prof.Dr. F. Lo Cocco (Rom, Italy): Member of the GIMEMA Study Group. Main priorities have been the conduction of numerous clinical trials in acute leukemias including intensive chemotherapy and transplantation and in addition monitoring of residual disease.

Prof.Dr. P. Martiat (Brussels, Belgium): Laboratory and clinical research experience in myeloproliferative disorders and lymphatic malignancies.

Prof.Dr. G. Martinelli (Bologna, Italy): Institute of Hematology and Medical Oncology "L. and A. Seràgnoli" S. Orsola University Hospital, Bologna. This research group has a longstanding interest in the biology of CML and the role of MRD monitoring in the treatment of patients with leukemia. They have extensive experience in RQ-PCR methodologies and have participated in Europe-wide initiatives to standardize detection of fusion gene targets in leukemia, such as the "Europe Against Cancer program".

M. Müller (, Germany):

Prof.Dr. G.J. Mufti (London, UK):

Dr. J. Nomdedeu (Barcelona, Spain): Research on mutational analysis of p53-mutations

E. Oppliger Leibundgut (, Switzerland):

Prof.Dr. G.J. Ossenkoppele (Amsterdam, Netherlands):

M. Ostergaard (, Denmark):

U. Ozbek (, Turkey):

Dr. R. Padua (London, UK):

Dr. N. Pallisgaard (Odense, Denmark): International reputation for molecular diagnostics, developing a multiplex PCR assay, which enables the detection of 30 translocations recurrently seen in leukemia. Development of RQ-PCR reactions for the most common fusion transcripts, which have been implemented in the clinical setting. Definition of the kinetics of BCR-ABL fusion transcript decline following Glivec treatment of IFN-resistant CML patients. Extensive experience of collaborative studies at the European level, being responsible for co-ordinating the Control Gene Network for the Europe Against Cancer RQ-PCR program.

Dr. F. Pane (Naples, Italy): University of Naples. This research group has a longstanding interest in the molecular characterization of CML and the development of RQ-PCR strategies for MRD detection. They have considerable experience in working in collaborative European studies and Dr. Pane recently co-ordinated the p190 Network for the "Europe Against Cancer" program. Current research interests are focusing on identification of T-cell clonotypes mediating graft versus leukemia activity in CML.

Dr. C. Preudhomme (Lille, France): Dept. of Hematology, Calmette Hospital CHU, Lille. Identification of genetic alterations in AML cases lacking chromosomal translocations, identifying point mutations in genes encoding transcription factors or receptor tyrosine kinases. Current research interests include identification of novel molecular markers in AML and comparison of molecular and immunological based methods for MRD detection. He is actively involved in establishing collaborative studies with other leukemia diagnostic laboratories in France, thereby providing a mechanism for spread of excellence beyond our Network.

PD Dr. A. Reiter (Heidelberg, Germany):

Dr. T. Sacha (Krakow, Poland): Experience in detection of residual disease and molecular studies on imatinib resistance in CML.

Prof.Dr. G. Saglio (Turin, Italy): University of Turin. This group has focused on the identification of molecular characterization and treatment of BCR-ABL associated CML. Longstanding interest in molecular diagnosis and MRD monitoring in other forms of leukemia, including evaluation of WT1 as a novel marker using RQ-PCR. Participated in numerous collaborative studies on CML and molecular diagnostics at the European level, including the BIOMED-1 and "Europe Against Cancer Programs" (Network leader for CBFß--MYH11).

V. Savchenko (, Russia):

N. Savva (, ):

Dr. S. Schnittger (Munich, Germany): Laboratory for Leukemia Diagnosis, Department of Internal Medicine, Klinikum Großhadern, Ludwig Maximillians University of Munich. Longstanding experience in identification of molecular and prognostic markers in AML, with a particular interest AML with normal karyotype. Responsible for co-ordinating molecular screening and MRD monitoring in AMLCG trial, in which RQ-PCR for the AML1-ETO, CBFB-MYH11, PML-RARA fusion is being used to monitor response. Participation in the German Leukemia Network in the Subgroup for MRD Detection.

G.J. Schuurhuis (, Netherlands):

Dr. C. Thiede (Dresden, Germany):

Dr. K. Tobal (Manchester, UK): Molecular Oncology Group, Dept. of Hematology, Manchester Royal Infirmary. Longstanding interest in MRD detection in AML and the development of competitive RT-PCR and RQ-PCR assays which are being evaluated in the context of the MRC AML15 trial.

G. Tsaur (, Russia):

Dr. V. van der Velden (Rotterdam, Netherlands): Dept. of Immunology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam. Focus on MRD detection and development of RQ-PCR assays in childhood acute leukemia.

Prof.Dr. J.J.M. van Dongen (Rotterdam, Netherlands): Dept. of Immunology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam. The focus of this research group is on MRD detection in childhood acute leukemia. During the last decade, several RQ-PCR assays for the detection of MRD have been developed. The Department has a leading and co-ordinating role in Europe on International collaborative studies to improve standards in molecular diagnostics and MRD detection, including BIOMED-1, BIOMED-2, I-BFM-SG MRD Task Force and „Europe Against Cancer“.

J. Yin (Manchester, UK): Molecular Oncology Group, Dept. of Hematology, Manchester Royal Infirmary. Member of the MRC Adult Leukemia Working Party and Member of the AML Working Group. Longstanding interest in MRD detection in AML and the development of competitive RT-PCR and RQ-PCR assays which are being evaluated in the context of the MRC AML15 trial.

A. Zaritskey (, Russia):